Xenetic Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Jim Parslow

İcra Kurulu Başkanı

US$433.7k

Toplam tazminat

CEO maaş yüzdesi	75.9%
CEO görev süresi	7.6yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	5.3yrs

Son yönetim güncellemeleri

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01

Recent updates

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01

Xenetic Biosciences reports Q2 results

Aug 12

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Aug 02

Xenetic inks clinical manufacturing contract with Catalent

Jul 07

Xenetic Biosciences reports Q3 results

Nov 13

CEO Tazminat Analizi

Jim Parslow'un ücretlendirmesi Xenetic Biosciences'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$4m
Jun 30 2024	n/a	n/a	-US$5m
Mar 31 2024	n/a	n/a	-US$4m
Dec 31 2023	US$434k	US$329k	-US$4m
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$4m
Mar 31 2023	n/a	n/a	-US$6m
Dec 31 2022	US$474k	US$329k	-US$7m
Sep 30 2022	n/a	n/a	-US$7m
Jun 30 2022	n/a	n/a	-US$7m
Mar 31 2022	n/a	n/a	-US$6m
Dec 31 2021	US$521k	US$299k	-US$6m
Sep 30 2021	n/a	n/a	-US$5m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$11m
Dec 31 2020	US$359k	US$285k	-US$11m
Sep 30 2020	n/a	n/a	-US$11m
Jun 30 2020	n/a	n/a	-US$14m
Mar 31 2020	n/a	n/a	-US$14m
Dec 31 2019	US$388k	US$265k	-US$18m
Sep 30 2019	n/a	n/a	-US$19m
Jun 30 2019	n/a	n/a	-US$10m
Mar 31 2019	n/a	n/a	-US$11m
Dec 31 2018	US$288k	US$265k	-US$7m
Sep 30 2018	n/a	n/a	-US$1m
Jun 30 2018	n/a	n/a	-US$2m
Mar 31 2018	n/a	n/a	-US$3m
Dec 31 2017	US$960k	US$199k	-US$4m

Tazminat ve Piyasa: Jim 'nin toplam tazminatı ($USD 433.73K ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 646.00K ).

Tazminat ve Kazançlar: Jim 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Jim Parslow (59 yo)

7.6yrs

Görev süresi

US$433,732

Tazminat

Mr. James F. Parslow, also known as Jim, has been Chief Financial Officer at Xenetic Biosciences, Inc. since April 03, 2017 and serves as its Chief Operating Officer and Corporate Secretary and serves as i...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Jeffrey Eisenberg	President & Director	8.3yrs	US$563.49k	0.027% $ 1.7k
Moshe Mizrahy	Independent Non Executive Director	less than a year	US$12.33k	0% $ 0
Roger Kornberg	Independent Director	8.8yrs	US$57.54k	0% $ 0
Firdaus Dastoor	Independent Director	10.8yrs	US$57.54k	0% $ 0
Dmitry Genkin	Non-Executive Director	less than a year	Veri yok	4.44% $ 276.6k
Guenther Koehne	Member of Scientific Advisory Board	5.5yrs	Veri yok	Veri yok
Matthew Frigault	Member of Scientific Advisory Board	5.8yrs	Veri yok	Veri yok
Alexey Vinogradov	Independent Director	5.3yrs	US$57.54k	Veri yok
Grigory Borisenko	Independent Non-Executive Director	5.2yrs	US$57.54k	0% $ 0
Maksim Mamonkin	Member of Scientific Advisory Board	4.8yrs	Veri yok	Veri yok
Allan Tsung	Member of Scientific Advisory Board	2.5yrs	Veri yok	Veri yok
Jonathan Spicer	Member of Scientific Advisory Board	2yrs	Veri yok	Veri yok

5.3yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: XBIO 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).

Xenetic Biosciences Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Xenetic Biosciences, Inc., Annual General Meeting, Dec 11, 2024

Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer

Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Xenetic Biosciences, Inc., Annual General Meeting, Dec 21, 2022

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Recent updates

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting Potential of Co-Administration of DNase I with CAR T Cells in Murine Model of Melanoma Lung Metastasis

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Xenetic Biosciences, Inc. Announces the Presentation of Positive Preclinical Data

Xenetic Biosciences, Inc., Annual General Meeting, Dec 11, 2024

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CLS Therapeutics Discloses its Views on Xenetic Biosciences

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform

Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Xenetic Biosciences, Inc., Annual General Meeting, Dec 21, 2022

Xenetic Biosciences Receives a Non-Compliance Letter from Nasdaq

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board

Price target increased to US$4.00

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xenetic Biosciences, Inc., Annual General Meeting, Dec 07, 2022

Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, Inc.

Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences reports Q2 results

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Xenetic inks clinical manufacturing contract with Catalent

Xenetic Biosciences Receives Written Notification from the Listing Qualifications Department of the Nasdaq

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding

High number of new directors

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$1.20 loss in 3Q 2020)

Consensus EPS estimates increase to -US$0.55

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.15 loss in 2Q 2020)

Price target increased to US$5.00

Xenetic Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

Xenetic Biosciences reports Q3 results

Xenetic Biosciences Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş